Plozasiran
Highest phase reached
Phase 3
Drug type
Oligonucleotide
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Oligonucleotide
- Drug name
- Plozasiran
- ads 005
- ads 005 free acid
- ADS-005
- ADS-005 FREE ACID
- plozasiran
- Plozasiran
- plozasiran [INN]
- PLOZASIRAN [USAN]
- Plozasiran [WHO-DD]
- plozasiran inn
- plozasiran usan
- plozasiran who dd
- ATC classification codes
- C10AX
- CAS registry numbers
- 2379776-40-4
- ChEMBL ID
- CHEMBL6068438
- RxNorm IDs (RxCUI)
- 2727175
- FDA ingredient codes (UNII)
- XG9ARL6P25
- Status
- Authorised
- Status date
- 19 Jun 2026
- Authorisation date
- 19 Jun 2026
- Approved indications
- Redemplo is indicated as an adjunct to diet to reduce triglyceride levels in adult patients with familial chylomicronaemia syndrome (FCS) (see section 4.2 for patient selection criteria).
- Product number
- EMEA/H/C/006579
- Authorisation holder
- Arrowhead Pharmaceuticals Ireland Limited
- Priority medicines scheme
- No
- Generic
- No
- Biosimilar
- No
- Generic medicines
- 0
- Biosimilar medicines
- 0
- Advanced therapy
- No
- Conditional approval
- No
- Additional monitoring
- Yes
- Accelerated assessment
- No
- Exceptional circumstances
- No
Therapeutic areas
- Hyperlipoproteinemia Type I
European medicines record
- Patents
- 0
- Designations
- 5
- First in class
- No
- Fast track
- Yes
- Breakthrough designation
- Yes
- Orphan designation
- Yes
- Priority review
- No
- Orphan exclusivity
- No
- Accelerated approval
- No
- Pharmacology name
- plozasiran
- Type
- Nucleic acid
- Approval recorded by Guide to Pharmacology
- Yes
- Condition
- Hypertriglyceridemia
- Highest recorded phase
- 1
- Condition identifier
- EFO:0004211
- Subject identifier
- D015228
- Condition
- Dyslipidemias
- Highest recorded phase
- 1
- Condition identifier
- HP:0003119
- Subject identifier
- D050171
- Condition
- Hyperlipoproteinemia Type I
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0009387
- Subject identifier
- D008072
- Condition identifier
- EFO_0004211
- Highest recorded phase
- 3
- Condition identifier
- HP_0003119
- Condition identifier
- MONDO_0002525
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005347
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0006515
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0009387
- Condition identifier
- MONDO_0009387
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0018637
- Highest recorded phase
- 3
- Condition identifier
- Orphanet_79211
- Highest recorded phase
- 2
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
Sequences
- Component
- Sequence
- Type
- Nucleic Acid
- Sequence
- (3'-5') U-G-C-C-C-U-G-U-C-A-U-A-A-G-A-G-U-C=A=C=U (5'-3') A-C-G-G-G-A-C-A-G-U-A-U-U-C-U-C-A-G-U-I-A
- 84141-025
Related records
Trials (8)
- A Phase 3 Study of ARO-APOC3 / VSA001 / SAR449124 (Plozasiran) in Chinese Adults With Familial Chylomicronemia Syndrome
- Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia
- Phase 3 Study of Plozasiran in Adults With Hypertriglyceridemia
- Study of ARO-APOC3 (Plozasiran) in Adults With Familial Chylomicronemia Syndrome (FCS)
- Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia
- Study of Plozasiran in Adults With Severe Hypertriglyceridemia
- Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute Pancreatitis
- Treatment Protocol of Plozasiran in Adults With High-Risk Severe Hypertriglyceridemia (SHTG) and in Adults and Adolescents With FCS
In development for (2)
- Familial lipoprotein lipase deficiency Phase 1
- Hypertriglyceridemia Phase 1